Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) saw a large growth in short interest in the month of December. As of December 29th, there was short interest totalling 1,196,544 shares, a growth of 38.4% from the December 15th total of 864,719 shares. Approximately 5.9% of the company’s stock are sold short. Based on an average trading volume of 289,382 shares, the short-interest ratio is presently 4.1 days.
In other Biohaven Pharmaceutical news, insider Robert Berman sold 160,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $25.76, for a total transaction of $4,121,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gregory Bailey sold 50,000 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $33.71, for a total transaction of $1,685,500.00. Following the transaction, the director now owns 2,516,701 shares in the company, valued at approximately $84,837,990.71. The disclosure for this sale can be found here. Insiders have sold a total of 983,608 shares of company stock worth $27,275,749 in the last quarter.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Biohaven Pharmaceutical by 1.1% in the fourth quarter. BlackRock Inc. now owns 1,154,207 shares of the company’s stock valued at $31,139,000 after purchasing an additional 12,505 shares during the last quarter. Eagle Asset Management Inc. grew its position in Biohaven Pharmaceutical by 20.4% during the fourth quarter. Eagle Asset Management Inc. now owns 1,104,999 shares of the company’s stock valued at $30,207,000 after buying an additional 187,243 shares during the period. Candriam Luxembourg S.C.A. bought a new position in Biohaven Pharmaceutical during the fourth quarter valued at about $2,158,000. Swiss National Bank bought a new position in Biohaven Pharmaceutical during the fourth quarter valued at about $413,000. Finally, Emerald Advisers Inc. PA grew its position in Biohaven Pharmaceutical by 52.0% during the fourth quarter. Emerald Advisers Inc. PA now owns 369,782 shares of the company’s stock valued at $9,977,000 after buying an additional 126,455 shares during the period. Institutional investors own 47.76% of the company’s stock.
Shares of Biohaven Pharmaceutical (NYSE BHVN) traded down $0.69 during mid-day trading on Friday, hitting $29.71. 419,481 shares of the stock traded hands, compared to its average volume of 431,276. The stock has a market capitalization of $1,070.00 and a P/E ratio of -5.69. Biohaven Pharmaceutical has a 52 week low of $17.00 and a 52 week high of $39.51.
Biohaven Pharmaceutical (NYSE:BHVN) last announced its earnings results on Tuesday, November 14th. The company reported ($1.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. analysts forecast that Biohaven Pharmaceutical will post -6.4 EPS for the current year.
Several research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Canaccord Genuity assumed coverage on shares of Biohaven Pharmaceutical in a report on Friday, December 15th. They set a “buy” rating and a $30.00 price objective on the stock. BidaskClub downgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, October 27th. Piper Jaffray Companies set a $48.00 price objective on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Monday, December 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Biohaven Pharmaceutical in a report on Wednesday, November 15th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $36.14.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.